First, I want to highlight data on the phase 2 2002 study of fazirsiran, formerly called ARO-AAT and TAK-999, presented in July at the EASL, International Liver Congress and published simultaneously in the New England Journal of Medicine. The presentation generated significant enthusiasm within the audience, welcoming positive data to address liver disease with no approved therapy and the validation of a New England Publication. Fazirsiran is a potential first-in-class investigational RNAi therapy designed to reduce production of a mutant form of alpha-1 antitrypsin protein called Z-AAT as a potential treatment for the rare genetic liver disease associated with alpha-1 antitrypsin deficiency, Z-AAT accumulation is believed to be the cause of progressing liver disease in patients with AAT deficiency.